We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Serum Autoantibody Against Interleukin -- 1α is Unrelated to the Etiology or Activity of Liver Disease but Can be Raised by Interferon Treatment.
- Authors
Itoh, Yoshito; Okanoue, Takeshi; Sakamoto, Shinichi; Nishioji, Kenichi; Kashima, Kei; Ohmoto, Yasukazu
- Abstract
Objective: To clarify the clinical significance of serum levels of interleukin-1α autoantibody in liver disease and their change during interferon therapy for chronic hepatitis. Methods: By radioimmunoassay, we studied the incidence of serum interleukin-1α autoantibody in 838 healthy controls and 180 patients with liver disease and monitored the change in antibody titer during the interferon therapy for chronic hepatitis. Results: We detected the interleukin-1α autoantibody in 12.6% (106/838) of healthy controls. In patients with liver disease, we found the antibody in 15.6% (5/32) in patients with acute hepatitis, 16.3% (13/80) in patients with chronic hepatitis, 18.8% (9/48) in patients with liver cirrhosis, and 15% (3/20) in patients with autoimmune liver disease. The incidence was not related to either etiology or inflammatory activity of liver disease. Two of three chronic hepatitis patients with initially high serum levels of the antibody (>2000 ng/ml) showed transient increase in antibody titers during interferon therapy. Conclusion: The serum level of interleukin-1α autoantibody was unrelated to the etiology or activity of liver disease. Interferon therapy can cause transient elevation of serum interleukin-1α antoantibody levels.
- Subjects
INTERLEUKIN-1; IMMUNOGLOBULINS; LIVER diseases; INTERFERONS; CHRONIC active hepatitis
- Publication
American Journal of Gastroenterology (Springer Nature), 1995, Vol 90, Issue 5, p777
- ISSN
0002-9270
- Publication type
Article